TNXP (Tonix Pharmaceuticals Holding) רווחיות מכירות לפי רווח גולמי

Tonix Pharmaceuticals focuses on fibromyalgia and CNS therapies while awaiting FDA approval for Tonmya. The massive potential of the chronic pain market paves the way for expanding the customer base. The operating gross margin demonstrates real profitability, where 84.00 determines the current value of the metric. The drug development process is accelerating through AI-driven molecular screening and automated tablet synthesis.
פילוחי מדדים פיננסיים ומדדי שוק עבור Tonix Pharmaceuticals (TNXP)

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of the core efficiency of profit generation. The current value of 84.00 and the gross margin profitability trend reflect the impact of Tonix Pharmaceuticals proprietary molecules, where a closed portfolio of CNS drugs reduces competition and stabilizes the realization value relative to development costs.